InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

  • INM-901 oral formulation shows encouraging results in preclinical studies
  • High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection
  • Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies
  • The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies

InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will be used in its development programs for Alzheimer’s disease following encouraging results obtained in preclinical trials (https://ibn.fm/D99wp).

INM-901 is a small molecule drug candidate that demonstrated multiple pharmacological effects in preclinical studies including neuroprotective effects, extending the length of neurites which is important for brain cell-to-cell communication, as well as reducing neuroinflammation. These preclinical studies…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.